• Cyberdyne's first-half net income attributable to shareholders fell 23% year-over-year to JPY 54 million, mainly on lower investment securities valuation gains.
• Operating loss narrowed 29% year-over-year to JPY 124 million, while revenue rose to JPY 2.01 billion.
• A German clinical trial supporting public health insurance coverage for HAL treatment began in August 2026, targeting 180 chronic spinal-cord-injury patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cyberdyne Inc. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.